Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy

León‐Castillo, Alicia; M. de Boer, Stephanie; Powell, Melanie; Mileshkin, Linda; Mackay, Helen; Léary, Alexandra; W. Nijman, Hans; Singh, Naveena; M. Pollock, Pamela; Bessette, Paul; Fyles, Anthony; Haie-Méder, Christine; T.H.B.M. Smit, Vincent; J. Edmondson, Richard; Putter, Hein; C Kitchener, Henry; J. Crosbie, Emma; de Bruyn, Marco; A. Nout, Remi; Horeweg, Nanda; L. Creutzberg, Carien; Bosse, Tjalling

doi:10.1200/jco.20.00549

Public

Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy

Published in Journal of Clinical Oncology • Aug 4, 2020

Authors:

Alicia León‐Castillo

Stephanie M. de Boer

Melanie Powell

Abstract

PURPOSE The randomized Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3) trial investigated the benefit of combined adjuvant chemotherapy and radiotherapy (CTRT) versus radiotherapy alone (RT) for women with high-risk endometrial cancer (EC). ...

Subject

Medicine

Endometrial cancer

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!